Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection.
Tight junctions (TJs) play a key role in maintaining bronchial epithelial integrity, including apical-basolateral polarity and paracellular trafficking. Patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) often suffer from chronic infections by the opportunistic Gram-negative bacterium Pseudomonas aeruginosa, which produces multiple virulence factors, including rhamnolipids. The macrolide antibiotic azithromycin (azm) has been shown to improve lung function in patients with CF without reducing the bacterial count within the lung. However, the mechanism of this effect is still debated. It has previously been shown that azm increased transepithelial electrical resistance (TER) in a bronchial epithelial cell line. In this study we used an air-liquid interface model of human airway epithelia and measured TER, changes in TJ expression and architecture after exposure to live P. aeruginosa PAO1, and PAO1-Deltarhl which is a PAO1 mutant lacking rhlA and rhlB, which encode key enzymes for rhamnolipid production. In addition, the cells were challenged with bacterial culture medium conditioned by these strains, purified rhamnolipids, or synthetic 3O-C(12)-HSL. Virulence factors secreted by P. aeruginosa reduced TER and caused TJ rearrangement in the bronchial epithelium, exposing the epithelium to further bacterial infiltration. Pretreatment of the bronchial epithelium with azm attenuated this effect and facilitated epithelial recovery. These data suggest that azm protects the bronchial epithelium during P. aeruginosa infection independent of antimicrobial activity, and could explain in part the beneficial results seen in clinical trials of patients with CF.
Halldorsson
Skarphedinn
S
Institute of Biology, Biomedical Center, University of Iceland, Landspitali, Eiriksgata 5, Reykjavik, Iceland.
Gudjonsson
Thorarinn
T
Gottfredsson
Magnus
M
Singh
Pradeep K
PK
Gudmundsson
Gudmundur Hrafn
GH
Baldursson
Olafur
O
D000199:Actins / Q000737:chemistry; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D017963:Azithromycin / Q000494:pharmacology*; D001980:Bronchi / Q000382:microbiology; D002460:Cell Line; D003550:Cystic Fibrosis / Q000382:microbiology; D003599:Cytoskeleton / Q000378:metabolism; D004847:Epithelial Cells / Q000378:metabolism / Q000382:microbiology*; D006801:Humans; D008055:Lipids / Q000737:chemistry; D018613:Microscopy, Confocal / Q000379:methods; D009154:Mutation; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000378:metabolism*; D019108:Tight Junctions; D037521:Virulence Factors / Q000378:metabolism
D000199:Actins; D000900:Anti-Bacterial Agents; D008055:Lipids; D037521:Virulence Factors; D017963:Azithromycin